Loading…

Health co-benefits and mitigation costs as per the Paris Agreement under different technological pathways for energy supply

[Display omitted] •Health co-benefits exceed mitigation costs for all technological pathways.•The global ratio health co-benefits to mitigation costs ranges from 1.45 to 2.19.•India and China show, by far, the greatest co-benefits.•Large co-benefits in 2030 demonstrate the need for urgent action.•In...

Full description

Saved in:
Bibliographic Details
Published in:Environment international 2020-03, Vol.136 (C), p.105513, Article 105513
Main Authors: Sampedro, Jon, Smith, Steven J., Arto, Iñaki, González-Eguino, Mikel, Markandya, Anil, Mulvaney, Kathleen M., Pizarro-Irizar, Cristina, Van Dingenen, Rita
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Health co-benefits exceed mitigation costs for all technological pathways.•The global ratio health co-benefits to mitigation costs ranges from 1.45 to 2.19.•India and China show, by far, the greatest co-benefits.•Large co-benefits in 2030 demonstrate the need for urgent action.•Integrated methodologies allow to capture the dynamics of air pollutants and CO2. This study assesses the reductions in air pollution emissions and subsequent beneficial health effects from different global mitigation pathways consistent with the 2 °C stabilization objective of the Paris Agreement. We use an integrated modelling framework, demonstrating the need for models with an appropriate level of technology detail for an accurate co-benefit assessment. The framework combines an integrated assessment model (GCAM) with an air quality model (TM5-FASST) to obtain estimates of premature mortality and then assesses their economic cost. The results show that significant co-benefits can be found for a range of technological options, such as introducing a limitation on bioenergy, carbon capture and storage (CCS) or nuclear power. Cumulative premature mortality may be reduced by 17–23% by 2020–2050 compared to the baseline, depending on the scenarios. However, the ratio of health co-benefits to mitigation costs varies substantially, ranging from 1.45 when a bioenergy limitation is set to 2.19 when all technologies are available. As for regional disaggregation, some regions, such as India and China, obtain far greater co-benefits than others.
ISSN:0160-4120
1873-6750
DOI:10.1016/j.envint.2020.105513